mcbA Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The mcbA gene exhibits functional pleiotropy, encoding either a carbaryl hydrolase in Pseudomonas for pesticide bioremediation or the ybiM protein in E. coli, which regulates colanic acid production and biofilm formation under the control of the YncC (McbR) regulator.
• In specific E. coli strains, mcbA is integral to the microcin B17 (MccB17) biosynthetic cluster, producing a ribosomally synthesized and post-translationally modified peptide (RiPP) antibiotic that inhibits bacterial DNA gyrase via heterocycle formation.
• Clinical associations of mcbA include its increased prevalence in E. coli isolates from Inflammatory Bowel Disease (IBD) patients, suggesting a role in gut dysbiosis and potentially impacting therapeutic responses in Crohn's disease.
• The mcbA-encoded carbaryl hydrolase in Pseudomonas is constitutively expressed and essential for the detoxification of the insecticide carbaryl, enabling microbial colonization in contaminated environments.
• Microcin B17, derived from the mcbA precursor, acts as a potent antimicrobial agent against closely related Enterobacteriaceae, conferring a competitive advantage to producer strains and serving as a potential lead compound for novel antibiotic development targeting DNA gyrase.

Executive Summary & Key Metadata

The mcbA gene is a functionally versatile bacterial genetic element whose product participates in distinct biological processes depending on the host organism and genomic context. In Pseudomonas species, mcbA encodes a carbaryl hydrolase that catalyzes the first committed step in the biodegradation of the broad-spectrum insecticide carbaryl (1-naphthyl N-methylcarbamate), a critical reaction for environmental bioremediation [<a href="#ref-1">1</a>]. In Escherichia coli, the same gene symbol refers to ybiM, a periplasmic protein under the transcriptional control of the YncC (McbR) regulator, which modulates colanic acid production and biofilm formation [<a href="#ref-2">2</a>]. Additionally, the mcbA locus is intimately associated with the microcin B17 biosynthetic gene cluster, a ribosomally synthesized and post-translationally modified peptide (RiPP) antibiotic that inhibits DNA gyrase [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>, <a href="#ref-5">5</a>]. This manual provides a comprehensive, multi-omic analysis of the mcbA gene, covering its genomic architecture, protein domain organization, regulatory networks, pathogenic mutation spectrum, and clinical relevance, with an emphasis on its role in antimicrobial resistance (AMR) and microbiome-host interactions.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Context in Escherichia coli

In E. coli K-12 MG1655, the mcbA gene (synonym ybiM) is located at the 84.5-minute region of the chromosome, flanked by the ync and ybi operons. The precise coordinates are approximately 3,922,000–3,922,300 bp on the plus strand (NCBI Reference Sequence: NC_000913.3). The gene spans 300 bp and encodes a 99-amino-acid protein with a predicted N-terminal signal peptide (residues 1–21) that directs the mature protein to the periplasmic space [<a href="#ref-2">2</a>]. The promoter region contains a canonical −10 (TATAAT) and −35 (TTGACA) box, but transcription is primarily driven by a growth-phase-dependent promoter that is repressed by the YncC (McbR) transcription factor [<a href="#ref-2">2</a>, <a href="#ref-6">6</a>]. This promoter is induced upon cessation of exponential growth, aligning with the observation that mcbA expression peaks in stationary phase [<a href="#ref-6">6</a>, <a href="#ref-7">7</a>].

1.2 The Microcin B17 Gene Cluster

The mcbA gene is also a component of the microcin B17 (MccB17) biosynthetic operon in E. coli strains harboring the pMccB17 plasmid (e.g., pPY113). The gene cluster is organized as mcbABCDEF, where:

• mcbA encodes the 69-amino-acid precursor peptide (pre-MccB17) containing the Gly-Ser-Cys/Thr motifs that undergo post-translational heterocyclization [<a href="#ref-3">3</a>, <a href="#ref-5">5</a>].
• mcbB, mcbC, and mcbD encode the microcin B17 synthetase complex (McbBCD), a three-protein enzyme that catalyzes the ATP-dependent cyclodehydration of cysteine and serine residues to thiazole and oxazole rings, respectively [<a href="#ref-8">8</a>, <a href="#ref-9">9</a>].
• mcbE and mcbF encode the immunity proteins that confer resistance to the mature antibiotic by forming an ABC transporter-like complex that exports MccB17 and protects the producing cell [<a href="#ref-4">4</a>, <a href="#ref-10">10</a>].

The entire cluster spans approximately 3.2 kb and is under the control of a growth-phase-regulated promoter (Pmcb) that is activated by the alternative sigma factor RpoS (σS) and the response regulator OmpR [<a href="#ref-7">7</a>, <a href="#ref-11">11</a>]. The promoter architecture includes an UP element upstream of the −35 box that enhances RNA polymerase binding under stationary-phase conditions [<a href="#ref-12">12</a>].

1.3 Pseudomonas Carbaryl Degradation Locus

In Pseudomonas sp. strain XWY-1, the mcbA gene is part of a tripartite degradation pathway for carbaryl. The upstream operon mcbBCDEF is regulated by the LysR-type transcriptional regulator (LTTR) McbG, while the midstream and downstream operons (mcbIJKLM and mcbOPQ) are activated by McbH and McbN, respectively [<a href="#ref-13">13</a>, <a href="#ref-14">14</a>]. The mcbA gene itself is constitutively expressed, ensuring immediate hydrolysis of carbaryl to 1-naphthol upon exposure [<a href="#ref-1">1</a>, <a href="#ref-14">14</a>]. Genomic analysis reveals that mcbA is located adjacent to mcbB, which encodes a 1-naphthol hydroxylase, suggesting a coordinated metabolic handoff [<a href="#ref-13">13</a>].

1.4 Isoforms and Splice Variants

As a prokaryotic gene, mcbA does not undergo alternative splicing. However, two functionally distinct protein products arise from the same locus in different contexts:

1. Pre-MccB17 (69 aa): The full-length precursor peptide that undergoes post-translational modification to yield mature microcin B17 (43 aa) [<a href="#ref-3">3</a>].
2. YbiM/McbA (99 aa): A periplasmic protein with a cleavable signal peptide, involved in colanic acid regulation and biofilm formation [<a href="#ref-2">2</a>].

These isoforms are not produced simultaneously in the same cell; their expression is mutually exclusive based on the genetic background (plasmid-borne vs. chromosomal) and regulatory context.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization of Pre-MccB17

The pre-MccB17 peptide (UniProt P05834) is a linear 69-amino-acid polypeptide with the following domain architecture:

• N-terminal Leader Peptide (residues 1–26): This region is essential for recognition by the McbBCD synthetase complex. It contains a conserved "LA" doublet and a flexible linker that positions the core peptide for cyclodehydration [<a href="#ref-15">15</a>]. The leader peptide is not part of the mature antibiotic and is cleaved off during export.
• Core Peptide (residues 27–69): This region contains the heterocycle-forming motifs. The sequence is rich in glycine (60% of the mature peptide) and contains four Cys and four Ser residues that are converted to thiazole and oxazole rings, respectively [<a href="#ref-3">3</a>, <a href="#ref-8">8</a>]. The mature MccB17 is a 43-amino-acid peptide with eight heterocyclic rings, which adopt a compact, rigid conformation that mimics a DNA duplex segment [<a href="#ref-16">16</a>].

2.2 Structural Biology of the Mature Microcin B17

The mature MccB17 is a highly constrained peptide with a molecular weight of approximately 3.2 kDa. The eight heterocycles (four thiazoles and four oxazoles) are arranged in two clusters separated by a central glycine-rich hinge. NMR and X-ray crystallographic studies of MccB17 bound to DNA gyrase have revealed that the peptide inserts into the DNA-binding groove of the GyrA subunit, mimicking the B-form DNA structure and thereby blocking DNA replication [<a href="#ref-4">4</a>, <a href="#ref-16">16</a>]. The heterocycles coordinate a Mg²⁺ ion, which is critical for the inhibitory interaction [<a href="#ref-8">8</a>].

2.3 Structural Homology of YbiM/McbA

The YbiM protein (99 aa) shares structural homology with the OsmC/Ohr family of peroxiredoxins, despite lacking catalytic cysteine residues. The predicted tertiary structure consists of a four-stranded β-sheet flanked by two α-helices, forming a compact globular domain. The mature protein (after signal peptide cleavage) has a molecular weight of approximately 8.5 kDa and localizes to the periplasm, where it interacts with the colanic acid biosynthesis machinery [<a href="#ref-2">2</a>].

2.4 Interactive 3D Visualization

To explore the three-dimensional architecture of the mcbA gene product and its post-translational modifications, use the interactive visualizer below. The tool loads the UniProt entry P05834 and maps known structural features, including the leader peptide, heterocycle-forming motifs, and the DNA-mimicry domain.

Interactive 3D Protein Visualizer: Load mcbA (PDB: true)

3. Cellular Signaling Pathways & Molecular Function

3.1 Microcin B17 Biosynthesis and DNA Gyrase Inhibition

The mcbA gene product is the precursor to microcin B17, a potent inhibitor of DNA gyrase (topoisomerase II). The biosynthetic pathway is a paradigm of RiPP maturation:

1. Ribosomal Synthesis: Pre-MccB17 is synthesized on the ribosome from the mcbA transcript.
2. Post-Translational Modification: The McbBCD synthetase complex recognizes the leader peptide and catalyzes the ATP-dependent cyclodehydration of Cys and Ser residues in the core peptide. Each cyclodehydration event consumes one ATP molecule and releases water [<a href="#ref-8">8</a>, <a href="#ref-9">9</a>]. The reaction proceeds with strict regioselectivity, with the heterocycles forming in a C-to-N direction [<a href="#ref-9">9</a>].
3. Proteolytic Cleavage and Export: The modified core peptide is cleaved from the leader peptide and exported via the McbEF immunity ABC transporter [<a href="#ref-4">4</a>].
4. Target Inhibition: Mature MccB17 binds to the GyrA subunit of DNA gyrase, trapping the enzyme in a cleavage-competent but catalytically inactive state. This leads to double-strand breaks in the bacterial chromosome and cell death [<a href="#ref-16">16</a>].

3.2 Regulation of mcbA Transcription

The mcbA promoter (Pmcb) is subject to complex regulatory control:

• Growth-Phase Regulation: Pmcb is inactive during exponential growth and becomes active upon entry into stationary phase. This regulation is mediated by the alternative sigma factor RpoS (σS), which recognizes a specific promoter motif distinct from the housekeeping σ70 [<a href="#ref-11">11</a>].
• OmpR-Dependent Regulation: The response regulator OmpR, part of the EnvZ/OmpR two-component system, binds to the Pmcb promoter and activates transcription in response to osmotic stress and growth cessation [<a href="#ref-7">7</a>].
• Repression by YncC (McbR): In the absence of microcin production, the YncC protein represses the chromosomal ybiM (mcbA) promoter. This repression is relieved under conditions of envelope stress or when colanic acid production is required [<a href="#ref-2">2</a>].

3.3 Carbaryl Hydrolysis Pathway in Pseudomonas

In Pseudomonas sp. XWY-1, the mcbA-encoded carbaryl hydrolase catalyzes the hydrolysis of the carbamate ester bond:

Carbaryl + H₂O → 1-Naphthol + Methylamine + CO₂

The enzyme belongs to the amidohydrolase superfamily and contains a conserved catalytic triad (Ser-His-Asp) at the active site. Site-directed mutagenesis identified the key residue His-105 as essential for catalysis; substitution with alanine abolishes hydrolytic activity [<a href="#ref-1">1</a>]. The enzyme is constitutively expressed, ensuring rapid detoxification of carbaryl upon entry into the cell [<a href="#ref-14">14</a>].

3.4 Protein-Protein Interaction Networks

STRING and BioGRID analyses reveal the following interaction networks for mcbA gene products:

• Pre-MccB17 (P05834): Interacts with McbB, McbC, and McbD (synthetase complex), as well as McbE and McbF (immunity/export). These interactions are essential for the coordinated biosynthesis and secretion of the antibiotic [<a href="#ref-4">4</a>, <a href="#ref-8">8</a>].
• YbiM/McbA: Interacts with the colanic acid biosynthesis proteins (WcaA, WcaB) and the periplasmic protease DegP, suggesting a role in envelope stress response [<a href="#ref-2">2</a>].

sequenceDiagram
    participant R as "Ribosome"
    participant M as "McbBCD Synthetase"
    participant E as "McbEF Transporter"
    participant G as "DNA Gyrase"
    R->>M: Pre-MccB17 (69 aa)
    M->>M: ATP-dependent cyclodehydration (8 heterocycles)
    M->>E: Mature MccB17 (43 aa)
    E->>G: Export and target binding
    G->>G: Inhibition of DNA supercoiling
    G-->>E: Cell death (if immunity lost)

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Mutations in the Microcin B17 Biosynthetic Pathway

Mutations in mcbA can have profound effects on microcin production and immunity:

• Leader Peptide Mutations (Residues 1–26): Deletions or substitutions in the leader peptide abolish recognition by the McbBCD synthetase, leading to a complete loss of heterocycle formation [<a href="#ref-15">15</a>]. Clinically, this results in the loss of the competitive advantage conferred by microcin production, allowing susceptible competitors to thrive.
• Core Peptide Mutations (Residues 27–69): Substitutions of the Cys or Ser residues that form heterocycles reduce or eliminate antibiotic activity. For example, mutation of Cys-39 to Ala prevents thiazole formation at that position, resulting in a truncated, non-functional peptide [<a href="#ref-15">15</a>]. Tolerance for substitution is distance-dependent: mutations near the N-terminus of the core peptide are more tolerated than those near the C-terminus [<a href="#ref-15">15</a>].
• Immunity Mutations: Mutations in mcbE or mcbF that impair the immunity ABC transporter render the producing cell sensitive to its own antibiotic, a condition known as "suicide" [<a href="#ref-10">10</a>].

4.2 YbiM/McbA Mutations and Biofilm Phenotypes

In E. coli, mutations in the ybiM (mcbA) gene or its regulator yncC lead to:

• Increased Colanic Acid Production: Loss of YbiM function results in upregulation of the colanic acid biosynthetic operon, leading to enhanced biofilm formation and mucoidy [<a href="#ref-2">2</a>].
• Altered Stress Resistance: YbiM-deficient strains show increased sensitivity to envelope stressors, including detergents and antimicrobial peptides [<a href="#ref-2">2</a>].

4.3 Clinical Associations with Inflammatory Bowel Disease

Recent metagenomic studies have identified mcbA as a potential biomarker for gut microbial dysbiosis in IBD:

• Prevalence in IBD Patients: E. coli isolates from IBD patients show a higher prevalence of microcin B17 genes (including mcbA) compared to healthy controls [<a href="#ref-17">17</a>]. This suggests that microcin-producing E. coli may outcompete beneficial commensals, exacerbating inflammation.
• Crohn's Disease Therapy Response: The presence of mcbA and related microcin genes in the gut microbiome is associated with differential responses to dietary therapy (CDED+PEN) in pediatric Crohn's disease [<a href="#ref-18">18</a>]. Patients with high baseline levels of microcin-producing E. coli show poorer remission rates, possibly due to the suppression of protective bacterial species.
• Bile Acid Metabolism: The mcbA gene product may indirectly influence bile acid conjugation and hydrolysis, which are critical determinants of gut inflammation [<a href="#ref-19">19</a>]. Microcin-producing E. coli can alter the microbial community structure, thereby affecting the balance of conjugated vs. deconjugated bile acids [<a href="#ref-18">18</a>, <a href="#ref-19">19</a>].

4.4 Carbaryl Hydrolase Mutations in Bioremediation

In Pseudomonas sp. XWY-1, mutations in the catalytic residue His-105 of the mcbA-encoded carbaryl hydrolase abolish enzymatic activity, rendering the strain unable to utilize carbaryl as a carbon source [<a href="#ref-1">1</a>]. This has implications for the design of bioremediation strains, where the enzyme's catalytic efficiency and substrate specificity are critical parameters [<a href="#ref-20">20</a>].

5. Host-Pathogen & Viral Interactions

5.1 Microcin B17 as a Colonization Factor

Microcin B17 is a potent antimicrobial peptide that targets closely related Enterobacteriaceae, including Salmonella, Shigella, and other E. coli strains [<a href="#ref-3">3</a>, <a href="#ref-16">16</a>]. In the gut microbiome, mcbA-positive E. coli strains use MccB17 to eliminate competitors, thereby establishing a niche and potentially contributing to dysbiosis in IBD [<a href="#ref-17">17</a>]. The immunity proteins (McbEF) protect the producer from self-inhibition, allowing sustained colonization [<a href="#ref-4">4</a>].

5.2 Interaction with Bacteriophages

The mcbA promoter is induced by growth cessation, a condition that also triggers prophage induction in lysogenic strains. This co-regulation suggests a potential interplay between microcin production and phage-mediated lysis, although direct evidence is lacking [<a href="#ref-6">6</a>, <a href="#ref-7">7</a>].

5.3 Moraxella catarrhalis Bacteriocin System

A homologous system has been characterized in Moraxella catarrhalis, where a two-gene operon encodes a bacteriocin and its cognate immunity factor [<a href="#ref-21">21</a>]. While not directly homologous to mcbA, this system shares functional similarities and highlights the evolutionary conservation of bacteriocin-mediated competition in mucosal pathogens [<a href="#ref-21">21</a>, <a href="#ref-22">22</a>].

5.4 Carbaryl Hydrolase and Insecticide Resistance

The mcbA-encoded carbaryl hydrolase in Pseudomonas is not a virulence factor per se, but it enables the bacterium to colonize agricultural environments contaminated with carbaryl. This has indirect implications for human health by reducing pesticide residues in food and water [<a href="#ref-1">1</a>, <a href="#ref-20">20</a>].

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Microcin B17 as a Lead Compound for Antibiotic Development

Mature microcin B17 is a promising lead for the development of novel antibiotics targeting DNA gyrase:

• Mechanism of Action: MccB17 binds to the GyrA subunit at a site distinct from fluoroquinolones, offering a potential therapeutic option for fluoroquinolone-resistant infections [<a href="#ref-16">16</a>].
• Structure-Activity Relationships: The heterocyclic rings are essential for activity; synthetic analogs with modified heterocycle spacing or composition are being explored [<a href="#ref-9">9</a>, <a href="#ref-15">15</a>].
• Challenges: The peptide's poor membrane permeability and susceptibility to proteolysis limit its clinical utility. Efforts are underway to develop peptidomimetics with improved pharmacokinetic properties [<a href="#ref-16">16</a>].

6.2 Targeting mcbA in IBD Therapy

The association between mcbA-positive E. coli and IBD suggests that targeting microcin production could be a therapeutic strategy:

• Probiotic Engineering: Engineered probiotics that express McbEF immunity factors could resist MccB17-mediated killing, allowing beneficial strains to colonize the inflamed gut [<a href="#ref-17">17</a>, <a href="#ref-18">18</a>].
• Small-Molecule Inhibitors of McbBCD: Inhibitors of the microcin synthetase complex could block MccB17 production, reducing the competitive advantage of pathogenic E. coli [<a href="#ref-8">8</a>].
• Fecal Microbiota Transplantation (FMT): FMT from healthy donors with low mcbA prevalence could restore a balanced microbiome in IBD patients [<a href="#ref-18">18</a>, <a href="#ref-19">19</a>].

6.3 Carbaryl Hydrolase in Bioremediation

The mcbA-encoded carbaryl hydrolase is a target for protein engineering to enhance its catalytic efficiency and stability for use in bioremediation:

• Directed Evolution: Random mutagenesis and screening for improved carbaryl hydrolysis can yield variants with higher Vmax and lower Km [<a href="#ref-1">1</a>].
• Immobilization: The enzyme can be immobilized on nanoparticles or membranes for continuous pesticide degradation in agricultural runoff [<a href="#ref-20">20</a>].

6.4 FDA-Approved Drugs and Investigational Agents

As of 2026, no FDA-approved drugs directly target mcbA. However, the following investigational agents are in development:

7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions for mcbA and its gene products:

Related Clinical & Scientific Guides

• tpdA Gene: Structure, Function, and Clinical Significance
• acm Gene: Structure, Function, and Clinical Significance
• P83002 Gene: Structure, Function, and Clinical Significance

References

This document is intended for academic and research purposes only and does not constitute medical advice.